A Double-blind, Randomized, Placebo Controlled, Dose Escalating Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Single Doses of GSK2330672 in Japanese Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2016
At a glance
- Drugs GSK 2230672 (Primary)
- Indications Cholestasis; Primary biliary cirrhosis; Pruritus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 08 Nov 2016 Status changed from recruiting to completed.
- 29 Jul 2016 Status changed from not yet recruiting to recruiting.
- 24 Jun 2016 New trial record